Moderna Inc (MRNA)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 1,927,000 | 1,644,000 | 2,478,000 | 2,051,000 | 2,907,000 | 2,932,000 | 3,801,000 | 3,441,000 | 3,205,000 | 3,027,000 | 2,873,000 | 5,048,000 | 6,848,000 | 5,550,000 | 5,603,000 | 5,442,000 | 2,624,000 | 1,505,580 | 1,761,630 | 391,720 |
| Short-term investments | US$ in thousands | 5,098,000 | 5,223,000 | 6,010,000 | 6,472,000 | 5,697,000 | 4,641,000 | 4,658,000 | 5,482,000 | 6,697,000 | 5,321,000 | 5,024,000 | 5,067,000 | 3,879,000 | 3,356,000 | 2,387,000 | 2,293,000 | 1,984,000 | 1,770,720 | 955,384 | 825,981 |
| Total current liabilities | US$ in thousands | 2,206,000 | 2,201,000 | 2,363,000 | 2,380,000 | 3,015,000 | 4,385,000 | 3,123,000 | 3,499,000 | 4,923,000 | 6,807,000 | 6,812,000 | 9,238,000 | 9,128,000 | 9,957,000 | 8,840,000 | 8,441,000 | 4,389,000 | 1,473,560 | 161,647 | 134,582 |
| Cash ratio | 3.18 | 3.12 | 3.59 | 3.58 | 2.85 | 1.73 | 2.71 | 2.55 | 2.01 | 1.23 | 1.16 | 1.09 | 1.18 | 0.89 | 0.90 | 0.92 | 1.05 | 2.22 | 16.81 | 9.05 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($1,927,000K
+ $5,098,000K)
÷ $2,206,000K
= 3.18
The cash ratio of Moderna Inc indicates the company's ability to cover its short-term liabilities with its cash and cash equivalents. A higher cash ratio is generally considered favorable as it suggests the company has enough liquid assets to meet its short-term obligations.
Analyzing the cash ratio trend of Moderna Inc over the period from March 31, 2020, to December 31, 2024, we can observe fluctuations in the ratio. The ratio started at a relatively high level of 9.05 on March 31, 2020, indicating a strong liquidity position. However, there was a significant increase in the cash ratio to 16.81 by June 30, 2020, suggesting an even stronger ability to cover short-term liabilities with cash.
Subsequently, the cash ratio declined gradually, reaching its lowest point of 0.89 on September 30, 2021. This decrease may raise concerns about Moderna Inc's liquidity position and its ability to meet short-term obligations solely from cash reserves.
The cash ratio showed some improvement from December 31, 2021, to March 31, 2024, fluctuating within a range of 0.92 to 3.58. This indicates that Moderna Inc managed to enhance its liquidity position, although there were still fluctuations in the ratio.
Overall, while Moderna Inc experienced fluctuations in its cash ratio over the period under review, the company has generally maintained a reasonable level of liquidity, with the ratio staying above 1 for most quarters. This suggests that Moderna Inc has had sufficient cash reserves to cover its short-term liabilities, although investors and analysts should continue monitoring the trend to ensure sustained liquidity strength.
Peer comparison
Dec 31, 2024